-
公开(公告)号：US20170096428A1
公开(公告)日：2017-04-06
申请号：US15382778
申请日：2016-12-19
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Christopher William am Ende , Douglas Scott Johnson , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04
CPC classification number: C07D471/04 , A61K31/4985
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I wherein X, R1, R2a, R2b, R4a, R4b, R5a, R5b, R6, R7, R10, R11, and y are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
-
![Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders](/abs-image/US/2015/11/24/US09193726B2/abs.jpg.150x150.jpg)
12.发明授权Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders 有权取代的吡啶并[1,2-a]吡嗪用于治疗神经变性和神经障碍公开(公告)号：US09193726B2
公开(公告)日：2015-11-24
申请号：US14543020
申请日：2014-11-17
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Douglas Scott Johnson , Chakrapani Subramanyam , Christopher John O'Donnell , Christopher William am Ende , Michael Eric Green , Nandini Chaturbhai Patel , Cory Michael Stiff , Tuan Phong Tran , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D241/36 , C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
![Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders](/abs-image/US/2014/12/23/US08916564B2/abs.jpg.150x150.jpg)
13.发明授权Substituted pyrido[1,2-a]pyrazines for the treatment of neurodegenerative and neurological disorders 有权取代的吡啶并[1,2-a]吡嗪用于治疗神经变性和神经障碍公开(公告)号：US08916564B2
公开(公告)日：2014-12-23
申请号：US14031163
申请日：2013-09-19
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Douglas Scott Johnson , Chakrapani Subramanyam , Christopher John O'Donnell , Christopher William am Ende , Michael Eric Green , Nandini Chaturbhai Patel , Cory Michael Stiff , Tuan Phong Tran , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: A61K31/4985 , C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
公开(公告)号：US20140088111A1
公开(公告)日：2014-03-27
申请号：US14031163
申请日：2013-09-19
Applicant: Pfizer Inc.
Inventor： Martin Youngjin Pettersson , Douglas Scott Johnson , Chakrapani Subramanyam , Christopher John O'Donnell , Christopher William am Ende , Michael Eric Green , Nandini Chaturbhai Patel , Cory Michael Stiff , Tuan Phong Tran , Gregory Wayne Kauffman , Antonia Friederike Stepan , Patrick Robert Verhoest
IPC: C07D471/04
CPC classification number: C07D471/04
Abstract: Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
Abstract translation: 公开了化合物的化合物和药学上可接受的盐，其中化合物具有说明书中定义的式I的结构。 还公开了相应的药物组合物，治疗方法，合成方法和中间体。
-
-
-
Search Results
14
records
(took 0.032 seconds)
